Edwards Lifesciences Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw 12.7% sales growth, driven by strong TAVR, TMTT, and Surgical performance, prompting raised full-year guidance for sales and EPS. Robust clinical evidence, innovation, and favorable market dynamics support continued growth across all segments.
-
Momentum in 2025 was driven by strong clinical data for TAVR and expanded mitral/tricuspid solutions, with 2026 growth guided at 6%-8%. Key clinical readouts and next-generation device launches are expected to support future growth, while margin expansion and focused R&D investment remain priorities.
-
The company is driving double-digit growth through innovation in TAVR, TMTT, and surgical therapies, with TMTT projected to reach $2 billion by 2030. Expansion into heart failure management and lifetime patient care strategies are key, while margin expansion and operational investments remain priorities.
-
Leadership transitions are underway with a strong internal bench, while the TAVR franchise benefits from robust clinical data and expanding indications. Financial guidance points to margin expansion and significant growth in the TMDT business, supported by ongoing product innovation and regulatory developments.
-
Leadership changes, strong TAVR growth, and new product launches are shaping the outlook, with regulatory updates and clinical trial data expected to drive further momentum. Recent acquisitions and a focus on innovation support long-term growth, while guidance remains confident for 2026 and beyond.
-
The conference highlighted a robust innovation pipeline in structural heart therapies, strong financial performance, and a clear focus on expanding patient access through next-generation products and regulatory support. Multiple catalysts are set to drive double-digit growth through 2030.
Fiscal Year 2025
-
Q4 and full-year 2025 saw double-digit sales growth, driven by strong TAVR and TMTT performance, new product launches, and strategic investments in patient access. 2026 guidance for 8%-10% sales growth and EPS of $2.90-$3.05 was reaffirmed, with continued margin expansion expected.
-
The company is positioned for 8%-10% sales growth in 2025, driven by TAVR, mitral, and tricuspid therapies, with double-digit EPS growth expected from 2026. Major catalysts include new clinical evidence, expanded indications, and global product launches, targeting 10% average annual growth long term.
-
Q3 2025 saw double-digit sales growth, driven by strong TAVR, TMTT, and surgical performance, with raised full-year guidance for sales and EPS. New clinical data and updated guidelines are fueling adoption, while FX and litigation remain key considerations.
-
Seven-year and ten-year data confirm TAVR's durability and equivalence to surgery, with new devices like SAPIEN 3 Ultra RESILIA and EVOQUE showing improved outcomes. The ENCIRCLE trial marks a milestone in mitral valve replacement, and ongoing innovation is expected to drive significant growth in valve therapies.
-
Q2 2025 saw double-digit sales growth and strong performance across all segments, leading to raised full-year guidance for both sales and EPS. TAVR, TMTT, and Surgical all posted robust growth, with new product approvals and global expansion driving momentum.
-
Strong financial performance and guidance are supported by robust supply chain management and flexible P&L strategies. Major growth catalysts include TAVR and TMTT innovations, regulatory milestones, and recent acquisitions, with multi-year expansion expected.
-
Q1 sales rose 8% to $1.41B, with strong TAVR and TMTT growth and key product milestones achieved. Full-year sales and EPS guidance maintained, with plans to offset tariff and acquisition headwinds. TMTT guidance was raised, and new product approvals and data support long-term growth.
-
Zoom is pivoting from a meetings-focused brand to a comprehensive work platform, emphasizing AI integration, monetization in high-value areas, and disciplined financial management. Growth will be driven by platform expansion, targeted M&A, and innovation in pricing and customer experience.
-
The company is focused on structural heart therapies, with TAVR and TMTT as key growth drivers. Margin expansion is expected from 2026, and new technologies like EVOQUE and PASCAL are set to expand market opportunities. Multi-source growth and strong capital allocation support a 10% organic revenue growth target.
-
The session highlighted a robust innovation strategy focused on structural heart disease, with major growth expected from TAVR, mitral, and tricuspid therapies. Financial guidance projects 8%-10% revenue growth in 2025 and double-digit EPS growth beyond, supported by ongoing R&D and targeted acquisitions.
Fiscal Year 2024
-
2024 sales grew 9% to $5.4B, with TMTT outperforming and TAVR steady. 2025 guidance targets 8%-10% sales growth, led by TAVR, TMTT, and Surgical, with operating margin expansion and robust cash reserves. Strategic acquisitions and new product launches position for long-term growth.
-
The event outlined a strategy focused on innovation in structural heart therapies, with diversified growth drivers in TAVR, mitral, and tricuspid segments, and emerging opportunities in heart failure and AR. Strong clinical evidence, global expansion, and robust financial guidance support a vision for 10% annual sales growth and double-digit EPS growth from 2026 onward.
-
TRISCEND II data show EVOQUE delivers significant, sustained improvements in tricuspid regurgitation and quality of life, with high technical success and strong demand from patients and physicians. The therapy is efficient, teachable, and poised for broader adoption as the market and evidence base grow.
-
EARLY TAVR trial data show a 50% reduction in major adverse events for asymptomatic severe AS patients treated early, challenging current watchful waiting guidelines. The findings are expected to expand the TAVR market by at least 20-40% and drive rapid adoption ahead of formal guideline changes.
-
Q3 sales grew 10% year-over-year, led by TAVR and TMTT, with adjusted EPS and margins above expectations. Guidance for 2024 remains unchanged, with one-time Q4 impacts anticipated. Strategic acquisitions and product launches position the company for continued growth.
-
Management reaffirmed strategic focus on structural heart disease, highlighted recent acquisitions as long-planned, and expects 2025 EPS to be lower before resuming growth in 2026. TAVR and TMTT remain key growth drivers, with new clinical data and regulatory milestones anticipated to boost adoption.
-
Q2 sales grew 8% year-over-year, led by strong TMTT growth, while TAVR underperformed due to hospital workflow constraints. Guidance for TAVR was lowered to 5%-7% growth, and two acquisitions were announced to expand into new therapeutic areas.
-
Management detailed the strategic sale of the critical care business to focus on structural heart, highlighted robust growth in TAVR and TMTT, and previewed upcoming clinical trial data that could expand patient access. New product launches and heart failure initiatives are set to drive future growth.
-
The conference highlighted a sharpened focus on structural heart therapies, with TAVR and TMTT as key growth drivers. New product launches, expanding clinical evidence, and strong market adoption—especially for SAPIEN 3 Ultra RESILIA and EVOQUE—are fueling optimism for continued growth.